Objective: To review the (1) reliability, validation, feasibility, and clinical utility and (2) the use of the Premature Infant Pain Profile (PIPP) from 1996 to 2009 to determine the effectiveness of pain management strategies.
P
ain is a complex biological, psychological, and social phenomenon. Given this complexity, the subjective individual nature of pain and the infants' inability to provide self-report, a comprehensive measurement approach combining reliable and valid indicators is required. [1] [2] [3] The Premature Infant Pain Profile (PIPP) 4 consists of 3 behavioral (facial actions: brow bulge, eye squeeze, and nasolabial furrow) and 2 physiological (heart rate and oxygen saturation) indicators, and 2 contextual [gestational age (GA) and behavioral state] variables that modify pain. The PIPP was developed 13 years ago and has steadily accumulated the evidence of reliability and validity. 5, 6 When compared with other infant pain measures, the PIPP is reported to be one of the most valid and reliable infant acute pain measures available. 7 However, a systematic evaluation of the measurement properties (reliability, validity, feasibility, and clinical utility) and the use of the PIPP as an outcome measure in efficacy and effectiveness trials have not been undertaken since its initial development. Therefore, a critical evaluation is timely and warranted.
Pain assessment is the cornerstone of effective management of pain and has been associated with the increased use of analgesia to decrease pain and suffering and to improve the quality of life. 8 The importance attributed to pain assessment has resulted in the development of approximately 3 dozen acute infant pain measures over the past 2 decades. 9, 10 However, all measures are not validated equally; widely varying degrees of psychometric performance, feasibility, and clinical utility exist. The rapid proliferation of measures provides a broad variety of instruments available for assessing acute pain in infants; yet, there is no single behavioral or biological measure or cadre of universally accepted, valid, reliable, and useful measures that would undisputedly meet the needs of researchers and ensure quality pain assessment and management in infants in clinical environments.
Given the infant's inability to self-report on a subjective phenomenon, pain is inferred from behavioral and physiological indicators. These indicators, either alone or in combination, have formed the basis for infant acute pain measures. In addition, functional indicators, such as sleeping and eating, and also developmentally appropriate social interaction and consolability, have been included as pain indicators in several pain measures. Functional indicators represent behavior that is sensitive (ie, change as a result of pain), but nonspecific (ie, the behavior varies with many events or conditions other than pain) to pain. The various indicators of pain could be construed as varying in sensitivity and specificity, either individually or collectively, and need to be more carefully explored in terms of these dimensions. Functional indicators have generally received less attention than behavioral indicators, such as facial actions, have little conceptual/theoretical clarity, and are usually poorly defined. 11 However, there is good reason to distinguish well-defined objective indicators from the vague, ambiguous terms that are subject to observer error and biased judgment used in many other scales.
Neurobehavioral state in infants is more clearly defined than consolability or social interaction, 12 and when assessed simultaneously with a painful event, can be considered as a contextual indicator or modifier. 2 For example, Grunau 13 and Grunau et al 14 reported that infants in a quiet sleep state responded less vigorously to a painful stimuli. Stevens and Johnston 15 and Stevens et al 16 corroborated these findings and have included this state as a contextual variable in the PIPP. The initial validation of the PIPP was conducted in terms of content and construct validation. Content validation was derived from a review of the literature and expert opinion. A full description of the content validation process can be found in the study of Stevens et al. 4 Construct validation was undertaken using extreme group comparisons on 4 empirical data sets from 3 different neonatal intensive care units (NICUs), including (1) data set 1 (from NICU1): GA=32 to 34 weeks, heel lance versus handling (n=124); 15, 16 (2) data set 2 (from NICU2): GA=32 to 34 weeks, heel lance versus handling (n=39) (Stevens and Johnston, unpublished data); (3) data set 3 (combined data sets 1 and 2 from NICU1 and NICU2): GA=28 to 30 weeks, heel lance versus Sham heel lance (n=47); 17 and (4) data set 4 (from NICU3): 37 to 40 weeks, circumcision (baseline vs. Gomco) (n=27). 18 Significant differences were found between PIPP scores in (1) nonpain (handling) versus pain (tissue-damaging heel lance) situations (P<0.0001 and Mann-Whitney U test; P<0.00001); (2) preterm infants (GA 28 to 30 wk) exposed to a heel lance versus Sham heel lance procedure (P<0.02; Mann-Whitney U test; Pr0.016); and (3) term infants (GA 37 to 40 wk) undergoing circumcision with topical analgesia versus no analgesia (P<0.02; Mann-Whitney U test; P<0.02). 4 The total PIPP score was lower in infants born at younger GA (28 to 30 wk) than older GA (32 to 34 wk). Internal consistency was demonstrated using Cronbach a coefficients for individual items that ranged from 0.59 for eye squeeze to 0.76 for behavioral state. The standardized item a coefficient for 6 of the items was 0.71, suggesting acceptable internal consistency. 4 GA was not included in the determination of the factor structure as it did not vary in the original sample used for this analysis (ie, all infants were between 32 and 34 wk of GA).
Recently, researchers have examined the relationship between behavioral pain indicators and cortical hemodynamic activity in response to noxious stimuli using nearinfrared spectroscopy. 19, 20 Slater et al 21 reported an overall very good correlation [regression coefficient=0.72; 95% confidence interval (CI): 0.32-1.11, P=0.001; correlation coefficient=0.57] between somatosensory cortical hemodynamic activity and the PIPP score. Behavioral indicators correlated best with cortical activity (regression coefficient=1.26; 95% CI: 0.84-1.67, P<0.0001; correlation coefficient=0.74). Some infants with cortical responses did not display associated facial action changes; resulting in low PIPP scores that could be interpreted as infants having no pain or pain of low severity. This finding is consistent with the finding of Johnston et al, 22 who reported that approximately 20% of infants did not respond behaviorally or physiologically to a painful stimulus. Cortical activation is a promising indicator of acute pain in infants but has yet to be validated adequately across infant populations or procedures.
The objective of this study was to review all relevant literature on the PIPP from 1996 to 2009 systematically in terms of (1) reliability, validation, feasibility, and clinical utility and (2) the use of the PIPP to determine the effectiveness of pain management strategies in infants.
METHODS

Data Sources
A comprehensive systematic review was undertaken using electronic literature search techniques conducted by a librarian at a university-affiliated pediatric hospital. 
Study Selection
Published studies were included in the review if they evaluated the reliability, validation, clinical utility, and the feasibility of the PIPP or if they were randomized controlled trials and intervention-related studies that used the PIPP as an outcome measure of pain.
Data Extraction
Data were extracted from each study by 2 pairs of raters (A.D. and J.L.; J.Y. and S.K.). For intervention studies, information on the researcher, study design, study sample, type of intervention, results, and quality rating was extracted. For the measurement studies, results were categorized by the psychometric or clinimetric property being evaluated.
Methodological quality for intervention studies was assessed independently by 2 pairs of raters (A.D., J.L.; J.Y. and S.K.). Studies were scored on a 4-point scale with 1 point allocated for each correctly executed step in the methodology. Scores were calculated based on the blinding of (a) randomization, (b) intervention, and (c) outcome measurements; and (d) completeness of follow-up. 23 Studies with a quality score of Z3 of 4 were considered to have high methodological quality and were included in the analysis. The final quality score was determined through consensus between the pairs of raters. If discrepancies existed, a third rater was consulted. Reliability and validity were assessed as per standard psychometric definitions by Streiner and Norman. 24 Reliability relates to the extent to which a measure can yield similar scores (ie, reproducibility) under different conditions. 24 Validity refers to evidence that a scale/tool is measuring what it is intending to measure. 24 Validation of a measure is achieved through correlation with existing scales or when no other measure exists, through experimental testing of the measure's constructs. 24 Feasibility, referred to the ease that a measure can be used in clinical practice. 25 Clinical utility captured how useful a measure is for health-related decision making concerning practice for an individual infant in a particular setting and context.
RESULTS
The search strategy yielded 62 unique studies for inclusion in the review. Search results are summarized in Figure 1 . Forty-eight studies (including 1 substudy 26 of a main study 7 ) used the PIPP as the major outcome in an intervention study and 14 studies focused on the measurement properties of the PIPP in newborn infants 24 to 48 weeks of GA (Table 1) .
Reliability
Reliability of the PIPP was reported in 5 studies 5, 6, 35, 37, 38 using Pearson r, Spearman p, and intraclass correlation coefficients. Interrater reliability was excellent (>0.89 for total score including all indicators). In 2 outcome studies 39, 40 that also reported information about reliability of the PIPP, both interrater and intrarater reliability scores were 0.95 (total score including all indicators). 41 Construct validation of the PIPP was undertaken using extreme groups comparisons such as pain versus nonpain stimuli and demonstrated by the ability of the measure to distinguish painful from nonpainful events (P<0.05) in 5 studies. 5, 28, 30, 35, 37 Norman et al 36 also compared pain responses to a heel lance versus alternative skin sites that included the forearm or calf, and reported that PIPP scores were lower when using alternative skin sites compared with the usual heel lance method.
Six researchers 6, [27] [28] [29] 32, 33 evaluated the convergent validation of the PIPP by comparing it with other validated infant pain measures. The PIPP was significantly and positively correlated with the Crying, Requires Increased oxygen, Increased vital signs, Expression, Sleeplessness (CRIES) measure in 3 studies. 6, 27, 28 In 2 separate studies, Ahn 27 and Ahn and Jun 28 reported that the PIPP was correlated with the CRIES for both painful and nonpainful procedures (r=0.447; P<0.001; r=0.292 to 0.472; P<0.005, respectively). McNair et al 6 reported that the PIPP was moderately correlated to the CRIES up to 24 hours postoperatively (intraclass correlation coefficient=0.6139; 95% CI: 0.4-0.76). Ahn and Jun 28 also reported a positive and significant correlation between the PIPP and the Face, Legs, Activity, Cry, Consolability measure (r=0.462 to 0.521; P<0.01). 28 The PIPP was highly correlated (r=0.81 to 0.83) with the Neonatal Pain, Agitation and Sedation Scale during severe pain but only moderately correlated (r=0.61) for minimal-to-moderate pain. 32 McNair et al 6 also reported that the PIPP was positively and highly correlated to the Visual Analog Scale (VAS) scores rated by health professionals, although no correlations were provided. No significant correlation was found between the PIPP and the Anderson Behavioral State Scoring System. 27 
Clinical Utility
Only 2 researchers addressed the clinical utility of the PIPP. Evans et al 31 reported that PIPP scores in very sick infants or infants exposed to multiple painful procedures may be lower than infants that are not as ill. Walden et al 38 recommended that the PIPP would be clinically useful in assessing pain in preterm infants 27 to 32 weeks of postconceptional age. Neither of the studies reported on how PIPP scores were used to make clinical decisions.
Feasibility
Four researchers assessed the feasibility of the PIPP. Three studies 5, 35, 37 reported that the PIPP was feasible; however, only the amount of training required by nurses was determined (ie, nurses required minimal training when using the measure). Ahn and Jun 28 proposed that the CRIES and Face, Legs, Activity, Cry, Consolability measure may have shown greater feasibility than the PIPP; however, the criteria used to determine feasibility were not specified.
Intervention Studies Using the PIPP
A total of 48 intervention studies using the PIPP were identified. Methodological quality of the studies included in the review was rated independently by 2 pairs of raters. If there was a discrepancy between the 2 pairs of raters, the final quality score was determined through discussion. If the discussion did not lead to consensus, a third rater was consulted. In 27 of 48 (56%) studies (Table 2) , raters scored at least 3 of 4 for methodological quality. The majority of researchers assessed the effect of the intervention on reducing acute pain during heel lance, 7, 26, 34, [42] [43] [44] [45] [46] [47] [48] [49] [50] venipuncture, 7, 26, 39, [51] [52] [53] [54] retinopathy of prematurity examinations [55] [56] [57] peripherally inserted central catheters, 40, 58, 59 ventilatory support, [60] [61] [62] circumcision, 63 and suprapubic aspiration. 64 In 17 of 27 (63%) studies with a quality score of Z3, the efficacy of the intervention was clearly delineated by significantly reduced PIPP scores during the most invasive phases of the heel lance procedure [45] [46] [47] 49, 50 63 and suprapubic aspiration. 64 In 10 of 27 (37%) studies no difference was showed between the comparison group and the intervention group, 7 of 10 (70%) studies also showed no difference with individual pain indicators (eg, cry and heart rate 39, 40, 43, 44 ) or with other validated pain measures. 42, 61, 62 
DISCUSSION
Given the absence of a biological gold standard for assessing pain in infants, 65 and the inability of infants to verbally articulate their pain, physiological (eg, heart rate) and behavioral (eg, facial action) indicators have been used either alone or combined in a multidimensional behavioral (eg, several types of behavioral indicators including facial expressions, cry, body movements) or composite (ie, both behavioral and physiologic indicators) measure to infer pain in infants. Optimal acute pain assessment in infants constitutes careful observation of the quality and quantity of pain indicators using reliable and valid measures.
This review of 62 studies supports the PIPP as a reliable, valid, feasible, and clinically useful measure for detecting differences in clinical outcomes. A high degree of reliability and validation of the PIPP have been established through both psychometric testing and use of the measure to determine outcomes in efficacy studies (Tables 1 and 2) ; however, there are limited data showing the clinical utility of the PIPP. Well-established psychometric properties (ie, reliability and validity) precede the determination of clinical utility. Therefore, the evaluation of the clinical utility of the PIPP, using clearly defined indicators, is necessary and timely. Von Baeyer and Spagrud 66 recently expanded the repertoire of clinical utility indicators to address accessibility of the measure on the web, ease in locating the measure, cost, disposable use (to address infection concerns), and availability in multiple languages; however, this definition aligns more with feasibility than clinical utility. A key challenge across measurement researchers is to clearly differentiate clinical utility and feasibility, and to more rigorously address and evaluate each of these measurement characteristics. On the basis of this review, further research is required to support the clinical utility of the PIPP and all infant pain measures.
Clinical utility is necessary before determining clinically significant differences or the meaningful differences in pain scores and outcomes to an individual. Powell et al 67 reported that the minimum clinically significant difference in VAS pain scores on children aged 8 to 15 years presenting in the hospital emergency department was 10 mm on a 100-mm VAS scale, which was comparable with adult reports. 68 Shah et al, 69 in soliciting opinions of parents and nurses, reported a minimum clinically important difference of 15% to 20% whereas other researchers suggest a 10% reduction may suffice for this difference. 67 These studies indicate that there is beginning consistency on an acceptable definition for the minimum clinically significant difference required in pain outcomes; however, methods of evaluating the broader criteria of clinical utility and feasibility as they apply to infant pain measures warrant further attention.
The clinical utility of the PIPP 4 and the CRIES 70 measures was assessed by Schiller 71 with regard to time, cost, instructions, acceptability, and format through a survey of NICU nurses after random assignment to instrument use and comparison of scores with a clinical pain expert. Both measures were rated as clinically useful, although the PIPP rated higher on acceptability and the CRIES rated higher on completion time and cost. 71 Other researchers, 31, 38 who have reported on clinical utility of the PIPP, have not clearly described methods for evaluating this construct.
Feasibility addresses the ease and effectiveness of applying a measure in practice. Feasibility involves evaluating the simplicity of scoring and interpretation, completion, cost, format, and training time. 72 In using the PIPP as an outcome measure for pain intensity in intervention studies, several feasibility issues need to be considered. A key question is "What is the true baseline period for comparison of the intervention"? For procedures such as a heel lance in a healthy term infant, the answer is straightforward in that baseline is established before handling the infant. However, for more complex procedures, such as surgery in a sick infant, assigning presurgical baseline values when it is assumed the infant is not experiencing pain is at best arbitrary and at worst an erroneous assumption. The timing associated with when to assess various PIPP indicators requires clearer instructions and consideration based on the particular context or use. Pillai Riddell and Racine 73 suggest caution when taking pain assessment at face value; the context or associated factors and implications are also critically important. Other issues such as variability in infant pain reactivity, infant temperament, and the impact of severity of illness are additional contextual factors that may modify pain response.
Although multidimensional behavioral infant pain measures have proliferated over the past decade, composite measures such as the PIPP (which included both behavioral and physiological indicators) may offer more breadth for pain assessment whereas multidimensional behavioral measures may provide greater depth in a particular dimension of pain indicator (eg, facial activity). For example, the Douleur Aigue¨du Nouveau-ne´7 4 is a multidimensional behavioral measure, including 3 dimensions of infant pain behavior. The Douleur Aigue¨du Nouveau-ne´has shown internal consistency, interrater reliability, and responsiveness to analgesic interventions. 52, 75, 76 Strong evidence for validation with the PIPP has also been established. 42, 52 High correlations between behavioral indicators are common; therefore, the value of expanding the variety of indicators beyond those that have already been validated in existing measures needs to be carefully considered to ensure that the scope of pain indicators is expanded to enhance validation without being redundant.
Although pain assessment has been significantly advanced with the advent of multiple new behavioral measures, trends in the development of these measures may have inadvertently limited understanding of pain in infants. 77 In particular, observation of a limited number of behaviors associated with a few painful procedures (eg, heel lance) over short time frames (eg, a few seconds to a few minutes) may have preempted exploration of a broader array of pain indicators in infants across different pain paradigms, states, and time domains. This approach has produced many similar or overlapping indicators represented in existing measures. Additional indicators warranting further exploration include skin conductance (palmar sweating 78 ), cortical indicators (eg, near-infrared spectroscopy [19] [20] [21] , and biomarkers (eg, heart rate variability). As we subscribe to the theory that pain is a multidimensional phenomenon, we support the position that composite scores provide the most comprehensive information about an infant's pain. However, data from the individual indicators frequently do not correlate highly across the broad age groups and developmental stages. 79 This inconsistency raises the dilemma of whether physiological and behavioral indicators, measured over the same time frame, are capturing the same or different dimensions of pain, and whether this diversity is supporting or distracting from the multidimensionality of this phenomenon. Careful evaluation of the nature of contributions from individual indicators and the relationship between them in multidimensional measures such as the PIPP is required in future research.
The capacity of observers to accurately assess multiple indicators simultaneously and well-defined observation periods for pain assessment can be facilitated by developing user-friendly training techniques. For the PIPP, we have developed an interactive training video with 4 vignettes of infants of varying GA and pain intensities. 80 Interactive educational methods such as electronic and web-based selflearning modules with authentic scenarios and real-time practice sessions address these issues and may enhance the use of assessment measures in the clinical setting.
CONCLUSIONS
Great strides have been made in pain assessment; yet, measures such as the PIPP have only been shown to be reliable and valid with acute procedural and postoperative pain; with limited research on clinical utility and feasibility. There remain large gaps in the assessment of prolonged, persistent, and chronic pain that preclude evidence-based optimal clinical pain management practices. 81 Further research evaluating the clinical effectiveness of health professionals, use of pain assessment measures, and factors that influence their use in practice is required. 68 The greatest challenge is ensuring that reliable and valid measures are used in practice to reduce suffering and enhance quality of life.
